This is the authors' abstract. We don't add key points for this paper.
Gout is a painful inflammatory arthritis associated with elevated uric acid (UA) levels in blood. Current monitoring methods rely on invasive blood testing and laboratory-based analysis, limiting frequent assessment. Here, we present LollyLab, a noninvasive lollipop-shaped electrochemical platform for salivary UA quantification, encouraging preventative lifestyle changes to reduce gout flare-ups and chronic joint deterioration. The device integrates sample collection, microfluidic transport, and sensing into a handheld format for point-of-care use. LollyLab employs Nafion-modified laser-induced graphene (LIG) electrodes and a phosphate-buffered saline preloaded glass fiber (PBS–GF) layer to enhance electrochemical performance in saliva. UA was quantified using square wave voltammetry (SWV) over a physiologically relevant range of 100–500 μ M. The platform achieved a sensitivity of 0.015 μ A μ M − 1 in real saliva ( R 2 = 0.999 ), a limit of detection of 12 μ M, and a limit of quantification of 40 μ M. Recovery studies demonstrated accuracies of 88.3%–102.6%. Human participant testing demonstrated close agreement with a commercial enzymatic assay, with relative errors below 15% across all subjects and strong user acceptance. Requiring only 90 μ l of saliva and approximately 90 s for analysis, LollyLab provides a low-cost and user-friendly platform for salivary UA monitoring with potential applicability to additional salivary biomarkers.
No takes yet. Share an insight, caveat, or question.
Ramos et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: